Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Aug 14 2025

0mins

Source: Yahoo Finance

Basilea Pharmaceutica's License Agreement: Basilea Pharmaceutica Ltd has entered an exclusive license agreement with Venatorx Pharmaceuticals to acquire global rights to ceftibuten-ledaborbactam etzadroxil, a promising oral treatment for complicated urinary tract infections (cUTI) caused by multidrug-resistant bacteria, which is ready for clinical phase 3 trials.
Financial Implications and Development Plans: The agreement includes upfront and milestone payments totaling up to USD 325 million, with an expected increase of CHF 15 million in R&D expenses for 2025. Basilea plans to initiate the registrational phase 3 program for cUTI within approximately 18 months.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

About the author

Top News

Ford Announces $19.5B EV Restructuring Charges

Fed Cuts Interest Rates Amid Economic Concerns

SpaceX Targets $800 Billion Valuation in Secondary Sale

U.S. Consumer Sentiment Slightly Improves in December

Related Articles

36Kr Successfully Hosts WISE 2025 Conference, Attracting Over 500 Million Views

OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%

People Also Watch